Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis.
Multiple sclerosis
T-cell subsets
absolute lymphocyte count
dimethyl fumarate
natalizumab
Journal
Multiple sclerosis journal - experimental, translational and clinical
ISSN: 2055-2173
Titre abrégé: Mult Scler J Exp Transl Clin
Pays: United States
ID NLM: 101668877
Informations de publication
Date de publication:
Historique:
received:
14
11
2019
revised:
24
01
2020
accepted:
04
02
2020
entrez:
23
5
2020
pubmed:
23
5
2020
medline:
23
5
2020
Statut:
epublish
Résumé
In patients treated with dimethyl fumarate, absolute lymphocyte count decline typically occurs during the first year and then plateaus; early drops have been associated with the development of severe prolonged lymphopenia. We investigated the effect of dimethyl fumarate on absolute lymphocyte counts and CD4+/CD8+ T cells in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in routine practice. Lymphocyte data were collected via medical chart abstraction. Primary endpoint: change from baseline in absolute lymphocyte count and CD4+/CD8+ counts at 6-month intervals following dimethyl fumarate initiation. Charts of 483 patients were abstracted and 476 patients included in the analysis. Mean baseline absolute lymphocyte count (2.23 × 10 Dimethyl fumarate-associated decline in absolute lymphocyte count in the first 12 months correlated with decline in CD4+ and CD8+ T cells and was independent of prior natalizumab. Absolute lymphocyte count monitoring continues to be an effective strategy to identify patients at risk of prolonged lymphopenia.
Sections du résumé
BACKGROUND
BACKGROUND
In patients treated with dimethyl fumarate, absolute lymphocyte count decline typically occurs during the first year and then plateaus; early drops have been associated with the development of severe prolonged lymphopenia.
OBJECTIVE
OBJECTIVE
We investigated the effect of dimethyl fumarate on absolute lymphocyte counts and CD4+/CD8+ T cells in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in routine practice.
METHODS
METHODS
Lymphocyte data were collected via medical chart abstraction. Primary endpoint: change from baseline in absolute lymphocyte count and CD4+/CD8+ counts at 6-month intervals following dimethyl fumarate initiation.
RESULTS
RESULTS
Charts of 483 patients were abstracted and 476 patients included in the analysis. Mean baseline absolute lymphocyte count (2.23 × 10
CONCLUSION
CONCLUSIONS
Dimethyl fumarate-associated decline in absolute lymphocyte count in the first 12 months correlated with decline in CD4+ and CD8+ T cells and was independent of prior natalizumab. Absolute lymphocyte count monitoring continues to be an effective strategy to identify patients at risk of prolonged lymphopenia.
Identifiants
pubmed: 32440353
doi: 10.1177/2055217320918619
pii: 10.1177_2055217320918619
pmc: PMC7227148
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2055217320918619Informations de copyright
© The Author(s) 2020.
Références
Neurol Neuroimmunol Neuroinflamm. 2015 Feb 12;2(3):e76
pubmed: 25738172
Neurol Clin Pract. 2016 Jun;6(3):220-229
pubmed: 27347439
Neurol Neuroimmunol Neuroinflamm. 2017 Mar 23;4(3):e340
pubmed: 28377940
Mult Scler Relat Disord. 2015 Jul;4(4):339-41
pubmed: 26195053
Front Immunol. 2017 Jun 07;8:652
pubmed: 28638382
Exp Gerontol. 2008 Feb;43(2):61-5
pubmed: 17870272
N Engl J Med. 2012 Sep 20;367(12):1098-107
pubmed: 22992073
Mult Scler Relat Disord. 2015 Jul;4(4):377-9
pubmed: 26195059
Acta Neurol Scand. 2018 Jun;137(6):623-625
pubmed: 29205270
Mult Scler Relat Disord. 2018 May;22:27-34
pubmed: 29524759
Mult Scler. 2016 Jul;22(8):1061-1070
pubmed: 26459150
N Engl J Med. 2012 Sep 20;367(12):1087-97
pubmed: 22992072
J Immunol. 2017 Apr 15;198(8):3069-3080
pubmed: 28258191